Skip to main content
OpenTrials

Clinical trial condition

Metastatic Solid Tumors

Explore clinical trials studying Metastatic Solid Tumors. Study availability and eligibility vary by location and protocol.

55 public trials 16 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Solid Tumors trial results

Completed

Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.

NCT02097810

Conditions
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Locations
  • UC Irvine Medical Center Orange, California, United States
  • University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • University Of Colorado Aurora, Colorado, United States
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
View Trial Details
Completed

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

NCT01928459

Conditions
Acrocephalosyndactylia, Advanced Solid Tumors, Bone Diseases, +18 more
Locations
  • H. Lee Moffitt Cancer Center & Research Institute Moffitt 4 Tampa, Florida, United States
  • University of Michigan Comprehensive Cancer Center SC Ann Arbor, Michigan, United States
  • Karmanos Cancer Institute Dept of Onc Detroit, Michigan, United States
  • Washington University School of Medicine Onc Dept St Louis, Missouri, United States
View all 22 locations
View Trial Details
Completed

Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

NCT02045602

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +12 more
Locations
  • Hospital Vall d'Hebron Barcelona, Spain
  • Institut Català d'Oncologia L'Hospitalet de Llobregat, Spain
  • Centro Integral Oncológico Clara Campal Madrid, Spain
  • Hospital Universitario Ramón y Cajal Madrid, Spain
View Trial Details
Completed

A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety

NCT01976143

Conditions
Advanced Cancer, Metastatic Solid Tumors
Locations
  • American Institute of Research, Los Angeles Los Angeles, California, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • University Hospitals Case-Medical Center Seidman Cancer Center Cleveland, Ohio, United States
View Trial Details
Completed

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors

NCT00793897

Conditions
Advanced Solid Tumors, Metastatic Solid Tumors, Neoplasms
Locations
  • Local Institution East Melbourne, Victoria, Australia
  • Local Institution Parville, Victoria, Australia
  • Local Institution Edmonton, Alberta, Canada
  • Local Institution Hamilton, Ontario, Canada
View Trial Details
Active, Not Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06031441

Conditions
Locally Advanced Solid Tumors, Metastatic Solid Tumors, Recurrent Solid Tumors
Locations
  • University of Alabama at Birmingham (UAB) Birmingham, Alabama, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • Icahn School of Medicine at Mount Sinai (ISMMS) New York, United States
  • The Ohio State University Columbus, Ohio, United States
View all 18 locations
View Trial Details
Active, Not Recruiting

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

NCT05853367

Conditions
Advanced Solid Tumors, Metastatic Solid Tumors, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • Northwestern Memorial Hospital ( Site 0002) Chicago, Illinois, United States
  • The University of Louisville, James Graham Brown Cancer Center ( Site 0004) Louisville, Kentucky, United States
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001) Hackensack, New Jersey, United States
  • Rutgers Cancer Institute of New Jersey ( Site 0005) New Brunswick, New Jersey, United States
View all 25 locations
View Trial Details

Related conditions